tiprankstipranks
pc:aeovi

Aeovian Pharmaceuticals

Aeovian Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted and highly selective small molecules that restore cellular metabolic quality control by inhibiting mTORC1 or CD38. The company’s lead candidate, AV078, is a first-in-class CNS-penetrant selective mTORC1 inhibitor in Phase 2 development for refractory epilepsy associated with tuberous sclerosis complex (TSC), a rare genetic disorder driven by hyperactive mTORC1 signaling. Aeovian is developing a pipeline of highly selective inhibitors with the potential to address multiple rare and age-related diseases.

Leadership & Board

Currently, no data available

Latest Estimated Valuation

Estimated Valuation
Estimated Valuation
Total Amount Raised$55M
Total Amount Raised$55M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$55M
Latest Funding Amount$55M
Latest Funding RoundSeries B
Latest Funding RoundSeries B
Post-Money Valuation
Post-Money Valuation

Funding Round

Funding Date
Funding Round
Amount Raised
Post-Money Valuation
Dec 16, 2025
Series B
$55.00M

Investors

Related News and Analysis